Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SFA-003
- Development stage
- Unknown
- Lead developer
- SFA Therapeutics
- Modality
- Small Molecules
01
Overview
SFA-003 is a novel small molecule drug candidate derived from natural substances produced in the human microbiome. It is being developed by SFA Therapeutics for the treatment of bullous pemphigoid, a rare autoimmune blistering skin disease. The drug operates through an immunomodulatory mechanism that targets multiple cellular pathways, representing a potential new approach to treating this serious condition with currently limited therapeutic options. As of mid-2025, SFA-003 is in late pre-clinical or early Phase 1 development and has not yet received orphan drug designation or regulatory approval[1][2][3].
- Other names
- SFA 003SFA003SFA-003
Beyond the preview
Go deeper on SFA-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SFA-003.